Abstract 2140P
Background
Metastases-directed stereotactic body radiotherapy (SBRT) in addition to standard of care systemic therapy is supported by randomized phase II trials and international practice guidelines for patients with an oligometastatic disease (OMD). However, little is known about quality of life (QoL) following SBRT, which would be valuable to better inform patient and clinicians in their decision-making process about the optimal multimodality treatment strategy.
Methods
OligoCare is a pragmatic prospective cohort study of E2-RADIatE, a collaboration between ESTRO and EORTC, which aims to identify patient, tumour, and treatment characteristics influencing overall survival after ablative radiotherapy for oligometastatic breast, colorectal, lung and prostate cancer. Patients are eligible irrespective of oligometastatic state (de-novo, repeat or induced), without restrictions to local or systemic therapy. Radical radiotherapy must be a component of treatment, irrespective of maximum number of metastases, as long as all cancer lesions are treated with radical intent. Assessment of QoL using the EORTC QLQ-C30 is optional. This analysis reports QoL at baseline and first FU (3-12 months) on the first 1600 enrolled patients.
Results
530 patients completed baseline QoL and 399 completed follow-up (median time after SBRT: 6 months). 71% of patients were male, with oligometastatic prostate cancer the most frequent primary (45%), followed by NSCLC (24%), breast (17%) and colorectal cancer (14%). WHO performance status was 0 or 1 in 87% of patients, median age was 69 years and median one single oligometastasis was treated with SBRT (range 1-8). Average global health status at baseline was 72 (SD 19.5), with higher baseline QoL in prostate cancer (average 78) as compared to NSCLC (average 65) or breast cancer (average 68) patients. Global health status remained stable during follow-up (average 72; SD 20), without differences between primary diseases. A more detailed assessment of QoL subdomains is underway.
Conclusions
Collection of QoL data was feasible in this prospective registry and early QoL remained stable following metastases-directed SBRT in oligometastatic breast, colorectal, lung and prostate cancer.
Clinical trial identification
NCT03818503.
Editorial acknowledgement
Legal entity responsible for the study
European Organisation for Research and Treatment of Cancer - EORTC.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07